Tannic Acid Nanoparticles for Exendin-4 Sustained Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Type 2 diabetes using glucagon-like peptide-1 (GLP-1) receptor agonists like exendin-4 face challenges due to short half-life and poor serum stability, leading to frequent injections and suboptimal release profiles from existing formulations, which hinder wider clinical applications.

Innovation Solution

A nanoparticle system comprising tannic acid, a trivalent metal ion, and a GLP-1 receptor agonist, formed through flash nanocomplexation, providing a sustained release of exendin-4 with improved stability and bioactivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If exendin-4 is packaged into PLGA microspheres for sustained release, then circulation time is extended, but particle size distribution becomes wide and colloidal stability is limited

Engineering Contradiction:

Improvecirculation timeVSAvoidcolloidal stability

Core Design Contradiction:

Duration of action of stationary objectVSStability of the object's composition

Solution Approach 1:

The patent uses a composite nanoparticle system combining tannic acid and albumin as the carrier material, rather than using a single polymer like PLGA. This composite structure provides both sustained release capability and improved colloidal stability through the synergistic properties of tannic acid (which forms stable complexes) and albumin (which provides biocompatibility and circulation longevity).

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent changes the physical parameters of the drug delivery system by reducing particle size to the nanoparticle range (20-200 nm) and controlling the drug loading concentration. This size reduction and parameter optimization improves both colloidal stability (through enhanced Brownian motion and reduced sedimentation) and circulation time (through improved tissue penetration and reduced reticuloendothelial system clearance).

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If exendin-4 is chemically modified through PEGylation or albumin conjugation to increase serum stability, then circulation time is extended, but drug bioactivity decreases

Engineering Contradiction:

Improvecirculation timeVSAvoiddrug bioactivity

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent uses tannic acid as an intermediary carrier that forms reversible complexes with exendin-4 through hydrogen bonding and hydrophobic interactions. This intermediary approach allows the drug to be protected during circulation (extending circulation time) while maintaining its ability to interact with the GLP-1 receptor (preserving bioactivity), avoiding the permanent structural modifications of PEGylation or conjugation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical state of drug delivery from free peptide to nanoparticle-encapsulated form, which alters the pharmacokinetic parameters (circulation time, distribution) without changing the chemical structure of exendin-4 itself. This parameter change approach maintains drug bioactivity while improving circulation characteristics.

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If exendin-4 is packaged into PLGA microspheres, then sustained release is achieved, but loading capability is poor (approximately 5%)

Engineering Contradiction:

Improvesustained releaseVSAvoiddrug loading capability

Core Design Contradiction:

Duration of action of stationary objectVSQuantity of substance

Solution Approach 1:

The patent replaces the mechanical entrapment mechanism of PLGA microspheres (where drug is physically trapped during polymerization) with a chemical complexation mechanism using tannic acid. Tannic acid forms strong reversible complexes with exendin-4 through multiple hydrogen bonds and hydrophobic interactions, enabling much higher drug loading capability (over 80% encapsulation efficiency) while maintaining sustained release through the gradual dissociation of these complexes.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanoparticle system achieves prolonged release of exendin-4, effectively regulating blood glucose levels and maintaining therapeutic effects for an extended period, as demonstrated in Type 2 diabetes mouse models, with improved patient compliance and reduced frequency of administration.

Implementation Method 1

the use of a flash nanocomplexation technique to prepare the nanoparticles

Methodology Applied

Scientific EffectChelation: Chemical Bonding

Implementation Method 2

providing a sustained release of exendin-4 with improved stability and bioactivity

Methodology Applied

Scientific EffectDiffusion: Diffusion

Data Source

PatentUS20220193200A1Tannic acid/fe (III) nanoparticles and methods of drug delivery

Publication Date: 2022.06.23 JOHNS HOPKINS UNIVERSITY

AI summary

Nanoparticle are described comprising a tannic acid, a trivalent metal ion, and a pharmaceutical agent comprising a water-soluble biologically active agent, such as a protein, a water-soluble peptide, small molecule or a combination thereof and methods of making and using the nanoparticles. Some nanoparticles of the present invention include 30-60% (w/w) of a tannic acid, 0.1-20% (w/w) of a trivalent metal ion, and 1-50% (w/w) of a pharmaceutical agent.